title: [Biomarker indicators of chemoprevention among subjects occupationally exposed to metals].
abstract: Chemoprevention with chelating agent Humetta for three months was performed, due to anaemia and other haematologic disorders, immunotoxicological alterations and/or increased chromosome aberration rate among galvanisers and goldsmiths occupationally exposed to precious and heavy metals. Twenty-two of altogether 47 subjects took part voluntarily in the chemoprevention, and the rest of the subjects served as untreated controls. Complex clinical laboratory testing including detailed anamneses; genotoxicological and immunotoxicological monitoring were performed before and after administration of chemopreventive agent. After chemoprevention a significant improvement was observed in anaemia and serum glucose levels, while a less marked improvement was found in serum cholesterol levels and liver functions. Altered chromosome aberration and apoptotic cell fraction also tended to normalise after treatment. Immunological parameters were not affected by the treatment. The obtained results may suggest that chemoprevention with chelating agents as Humetta can help in the prevention of harmful effects of occupational exposures to metals.
authors.affiliation: Országos Kémiai Biztonsági Intézet, Fodor József Országos Közegészségügyi Központ, Budapest, 1450, Hungary. majorj.okbi@okk.antsz.hu
authors.forename: Jenô
authors.initials: J
authors.lastname: Major
authors.forename: Mátyás
authors.initials: M
authors.lastname: Jakab
authors.forename: Anna
authors.initials: A
authors.lastname: Biró
authors.forename: Tibor
authors.initials: T
authors.lastname: Klupp
authors.forename: Balázs
authors.initials: B
authors.lastname: Magyar
authors.forename: Katalin
authors.initials: K
authors.lastname: Gál
authors.forename: Gábor
authors.initials: G
authors.lastname: Oláh
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Fodor
authors.forename: Anna
authors.initials: A
authors.lastname: Tompa
mesh_terms: D015415:Biomarkers / Q000097:blood; D002614:Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002869:Chromosome Aberrations / Q000139:chemically induced; D004249:DNA Damage / Q000187:drug effects / Q000276:immunology; D005260:Female; D006402:Hematologic Diseases / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D008213:Lymphocyte Activation; D016131:Lymphocyte Subsets; D008297:Male; D019216:Metals, Heavy / Q000009:adverse effects*; D008875:Middle Aged; D009152:Mutagenicity Tests / Q000379:methods; D009153:Mutagens / Q000009:adverse effects*; D009784:Occupational Diseases / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D016273:Occupational Exposure / Q000009:adverse effects; D012907:Smoking / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D002614:Chelating Agents; D019216:Metals, Heavy; D009153:Mutagens